Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
SNAP-8
Also known as: Acetyl Octapeptide-3, Acetyl Glutamyl Heptapeptide-1
SNAP-8 is a synthetic octapeptide designed as an extension of the hexapeptide Argireline (acetyl hexapeptide-3). It is marketed primarily as a topical cosmeceutical for wrinkle reduction. The peptide mimics the N-terminal end of SNAP-25, a protein involved in neuromuscular junction signaling. Evidence is almost entirely from manufacturer-sponsored in vitro and small cosmetic studies.
Risk Level
Low RiskDifficulty
Beginner| CAS Number | 868844-74-0 |
| Molecular Formula | C41H68N14O16S |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Competes with SNAP-25 for positions in the SNARE complex, which is required for vesicle fusion and acetylcholine release at neuromuscular junctions. By destabilizing SNARE complex formation, it reduces neurotransmitter release and muscle contraction intensity, producing a mild botulinum-toxin-like effect topically.
Dosing Research
Used topically at 3-10% concentration in serums and creams, applied once or twice daily to targeted facial areas. Not typically injected. Effects are gradual and require consistent application over 4-8 weeks. Often combined with other cosmetic peptides.
Side Effects & Risks
Topical use is generally well-tolerated with rare skin irritation or contact sensitivity. Penetration through intact skin is limited, reducing systemic risk. No significant adverse events reported in cosmetic use studies.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.